Laurence Entsuah is a Gastroenterology physician. OpenAlex indexes 6 publications with 540 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1548 Sheridan Dr
Suite 100a
Lancaster, OH 431303360
Telephone
740-681-9575Registry record last updated 11 Apr 2013.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year20253 payments
- Janssen Biotech, Inc.Program year20251 payment
- Regeneron Healthcare Solutions, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
50%Proton pump inhibitor50%Dexilant100%Part D<11 patientsAnti-infectives
50%Macrolide Antimicrobial50%Azithromycin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Patients with Multiple Endocrine Neoplasia Type 1 with Gastrinomas Have an Increased Risk of Severe Esophageal Disease Including Stricture and the Premalignant Condition, Barrett’s Esophagus
The Journal of Clinical Endocrinology & Metabolism
2006 - Cutaneous Tumors in Patients with Multiple Endocrine Neoplasm Type 1 (MEN1) and Gastrinomas: Prospective Study of Frequency and Development of Criteria with High Sensitivity and Specificity for MEN1
The Journal of Clinical Endocrinology & Metabolism
2004 - Development of Bombesin Analogs with Conformationally Restricted Amino Acid Substitutions with Enhanced Selectivity for the Orphan Receptor Human Bombesin Receptor Subtype 3
Journal of Pharmacology and Experimental Therapeutics
2004 - Prospective Study of Thymic Carcinoids in Patients with Multiple Endocrine Neoplasia Type 1
The Journal of Clinical Endocrinology & Metabolism
2003
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Charles Rice, MD
The Rockefeller University
Edward Loftus, MD
Mayo Clinic Rochester
Naga Chalasani, MD
Indiana University School of Medicine
Bruce Sands, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”